I will be discussing the strategic considerations for Inter Partes Review (IPR) versus Ex Parte Reexamination, including:
- The procedural differences between IPR and Ex Parte Reexamination and associated statistics
- The circumstances when one may be preferable over the other
- The effects of timing and estoppel in parallel litigations
My colleague, Jason Murata, another partner in Axinn's Intellectual Property group, will be covering, "Recent Developments in the Generic Pharma Industry in the U.S."
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.